{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:13:22Z","timestamp":1783977202403,"version":"3.55.0"},"reference-count":28,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>(1) Objective: The main aims of our study were to explore the drug survival and effectiveness of secukinumab in patients with axial spondyloarthritis (axSpA). (2) Methods: We underwent a retrospective analysis of consecutive axSpA treated with secukinumab as a first line of biologics or at switch in a biologic-experienced population. Efficacy data, indicating improvement in inflammation parameters (such as C-reactive protein and erythrocyte sedimentation rate) and disease activity scores (such as Ankylosing Spondylitis Disease Activity Score [ASDAS-CRP], Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), and patient-reported outcomes (pain), were assessed at 6, 12, 24, 36 and 48 months. The drug survival rate, dropout rate and discontinuation reasons (efficacy versus safety) of secukinumab were assessed in subgroup analysis (axSpA with and without exposure to biologics). (3) Results: In total, 46 patients were exposed to the IL-17A inhibitor secukinumab. The drug survival for axSpA patients 59.7% at 12 months and 31.3% at 24 months. There were no statistically significant differences in the median drug survival between biologic-na\u00efve versus biologic-experienced subgroups. (4) Conclusions: Secukinumab has demonstrated effectiveness and safety in treating a cohort of axSpA patients in real-world settings, with a notable retention rate of the drug.<\/jats:p>","DOI":"10.3390\/jpm14040417","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T10:24:26Z","timestamp":1713176666000},"page":"417","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Drug Survival, Effectiveness and Safety of Secukinumab in Axial Spondyloarthritis up to 4 Years: A Real-Life Single Center Experience"],"prefix":"10.3390","volume":"14","author":[{"given":"Alexandra-Diana","family":"Diaconu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania"},{"name":"Internal Medicine 2nd Department, \u2018\u2018Sf\u00e2ntul Spiridon\u2019\u2019 Emergency Clinical County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pom\u00eerleanu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania"},{"name":"Rheumatoloy 2nd Department, Clinical Rehabilitation Hospital, 14 Pantelimon Halipa Street, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Russu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania"},{"name":"Rheumatoloy 2nd Department, Clinical Rehabilitation Hospital, 14 Pantelimon Halipa Street, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5089-7202","authenticated-orcid":false,"given":"Georgiana","family":"Strugariu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania"},{"name":"Rheumatoloy 2nd Department, Clinical Rehabilitation Hospital, 14 Pantelimon Halipa Street, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Ancu\u021ba","sequence":"additional","affiliation":[{"name":"Research Department, Elena Doamna Clinical Hospital, 700398 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Ciortescu","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania"},{"name":"Institute of Gastroenterology and Hepatology, \u201cSf\u00e2ntul Spiridon\u201d Emergency Clinical County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bologa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania"},{"name":"Internal Medicine 2nd Department, \u2018\u2018Sf\u00e2ntul Spiridon\u2019\u2019 Emergency Clinical County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Mor\u0103ra\u0219u","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania"},{"name":"Internal Medicine 2nd Department, \u2018\u2018Sf\u00e2ntul Spiridon\u2019\u2019 Emergency Clinical County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Constantin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania"},{"name":"Internal Medicine 2nd Department, \u2018\u2018Sf\u00e2ntul Spiridon\u2019\u2019 Emergency Clinical County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0043-9051","authenticated-orcid":false,"given":"Alexandr","family":"Ceasovschih","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania"},{"name":"Internal Medicine 2nd Department, \u2018\u2018Sf\u00e2ntul Spiridon\u2019\u2019 Emergency Clinical County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1721-2360","authenticated-orcid":false,"given":"Victori\u021ba","family":"\u0218orodoc","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania"},{"name":"Internal Medicine 2nd Department, \u2018\u2018Sf\u00e2ntul Spiridon\u2019\u2019 Emergency Clinical County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren\u021biu","family":"\u0218orodoc","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania"},{"name":"Internal Medicine 2nd Department, \u2018\u2018Sf\u00e2ntul Spiridon\u2019\u2019 Emergency Clinical County Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-8121","authenticated-orcid":false,"given":"Codrina","family":"Ancu\u021ba","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania"},{"name":"Rheumatoloy 2nd Department, Clinical Rehabilitation Hospital, 14 Pantelimon Halipa Street, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.12688\/f1000research.22577.1","article-title":"Recent advances in managing axial spondylarthritis","volume":"9","author":"Agrawal","year":"2020","journal-title":"F1000Research"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"587119","DOI":"10.3389\/fimmu.2021.587119","article-title":"Multi \u2019Omics Analysis of Intestinal Tissue in Ankylosing Spondylitis Identifies Alterations in the Tryptophan Metabolism Pathway","volume":"12","author":"Berlinberg","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/rheumatology\/keaa250","article-title":"Classification vs diagnostic criteria: The challenge of diagnosing axial spondyloarthritis","volume":"59","author":"Poddubnyy","year":"2020","journal-title":"Rheumatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"591176","DOI":"10.3389\/fimmu.2020.591176","article-title":"Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies","volume":"11","author":"Hammitzsch","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","first-page":"282","article-title":"Update of the American College of Rheumatology\/ Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"68","author":"Ward","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_8","unstructured":"Ancu\u021ba, C., and Pom\u00eerleanu, C. (2019). Principii de Diagnostic \u0219i Tratament \u00een Reumatologie, Editura \u201cGr. T. Popa\u201d, Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/1756-185X.14008","article-title":"Development of a Bangla version of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI)","volume":"24","author":"Abdal","year":"2021","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/1756-185X.13735","article-title":"Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore","volume":"22","author":"Kwan","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: A randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/14397595.2018.1538004","article-title":"Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)","volume":"30","author":"Kishimoto","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2021-220420","article-title":"Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: Does the choice of biological therapy matter?","volume":"80","author":"Bengtsson","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","article-title":"Interleukin-17 inhibition: Role in psoriasis and inflammatory bowel disease","volume":"29","author":"Hohenberger","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1097\/CM9.0000000000001099","article-title":"Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: Results from the 52-week, Phase III China-centric study, MEASURE 5","volume":"133","author":"Huang","year":"2020","journal-title":"Chin. Med. J. (Engl.)"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40744-022-00446-9","article-title":"Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry","volume":"9","author":"Freire","year":"2022","journal-title":"Rheumatol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_20","first-page":"50","article-title":"MEASURE 1 Study Group. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF- naive and anti-TNF-experienced subjects with active ankylosing spondylitis: Results from the MEASURE 2 study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"679009","DOI":"10.3389\/fmed.2021.679009","article-title":"Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: SEcukinumab in Cantabria and ASTURias study","volume":"8","author":"Alonso","year":"2021","journal-title":"Front. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"002802","DOI":"10.1136\/rmdopen-2022-002802","article-title":"Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: Results from a retrospective study (FORSYA)","volume":"9","author":"Dougados","year":"2023","journal-title":"RMD Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3899\/jrheum.220824","article-title":"Real-world retention and clinical effectiveness of secukinumab for axial spondyloarthritis: Results from the Canadian spondyloarthritis research network","volume":"50","author":"Inman","year":"2023","journal-title":"J. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/acr2.11139","article-title":"Incidence of Uveitis in Secukinumab-treated Patients with Ankylosing Spondylitis: Pooled Data Analysis from Three Phase 3 Studies","volume":"2","author":"Deodhar","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"ref_27","first-page":"1131","article-title":"Emergence of Inflammatory Bowel Disease During Treatment with Secukinumab","volume":"12","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: A retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/4\/417\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:27:59Z","timestamp":1760106479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/4\/417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["jpm14040417"],"URL":"https:\/\/doi.org\/10.3390\/jpm14040417","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}